CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 17 enrolled
Drug / intervention
Dexcom Seven Plus Continuous Glucose Monitoring Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01165775
NCT01165775N/ACompleted

Continuous Glucose Monitoring in Pregnant Women Undergoing Betamethasone Therapy

Stanford University·observational·Posted Jul 20, 2010·Updated Sep 16, 2016

In Brief

An observational study evaluating Dexcom Seven Plus Continuous Glucose Monitoring System for Pregnancy Complications. Completed, enrolled 17 participants across 1 site.

Detailed Summary

We hope to clarify how betamethasone affects glucose levels in the mother in the days after receiving the drug. This understanding will hopefully allow us to better anticipate the risk of maternal hyperglycemia and therefore establish more appropriate monitoring of maternal glucose to prevent maternal and neonatal complications of hyperglycemia.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 20, 2010
Enrollment StartJul 1, 2010
Primary CompletionJun 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 16.0 years ago

Interventions

Dexcom Seven Plus Continuous Glucose Monitoring Systemdevice

Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.